Welcome to our dedicated page for Boston Scien Cp SEC filings (Ticker: BSX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Boston Scientific Corporation (NYSE: BSX) files a broad range of reports and disclosures with the U.S. Securities and Exchange Commission, providing detailed insight into its operations as a global medical technology company. These SEC filings cover topics such as financial performance, material acquisitions, executive compensation programs, governance changes and risk factors relevant to the business.
On this page, you can review Boston Scientific’s current reports on Form 8-K, which the company uses to announce material events. Recent 8-K filings describe the definitive agreement to acquire Penumbra, Inc., including references to a joint press release and investor presentation, as well as the adoption of a 2026 annual bonus plan and performance share programs tied to metrics like global sales, adjusted earnings per share, relative total shareholder return and organic net sales growth. Other 8-Ks report quarterly financial results, director retirement plans and changes in senior leadership roles.
In addition to 8-Ks, Boston Scientific’s annual reports on Form 10-K and quarterly reports on Form 10-Q (accessible via the SEC’s EDGAR system) include consolidated financial statements, segment and geographic net sales data, discussions of MedSurg and Cardiovascular businesses, and extensive risk factor sections. These filings also explain the company’s use of non-GAAP financial measures such as operational and organic net sales growth and adjusted earnings per share, with reconciliations to GAAP figures.
Stock Titan enhances these regulatory documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify information on acquisitions, compensation plans, performance metrics and risk disclosures. Real-time updates from EDGAR ensure that new Boston Scientific filings, including Forms 10-K, 10-Q and 4 (insider transaction reports), are added as they become available, while AI-generated explanations assist in interpreting complex financial and legal language.
Boston Scientific arranged new bank financing to support its planned acquisition of Penumbra and refresh its liquidity facilities. The company entered into a $3.0 billion multi-year revolving credit agreement maturing on February 26, 2031, with interest tied to its credit rating and a required maximum leverage ratio.
It also put in place a $2.0 billion 364-day revolving credit facility and a $6.0 billion delayed draw term loan agreement, split into two 364-day tranches that can be drawn at the Penumbra acquisition closing. Tranche B borrowings must later be repaid or refinanced with proceeds from future equity or debt offerings, and both the revolvers and term loans carry ticking fees on undrawn commitments.
Following these new agreements, Boston Scientific terminated its prior revolving credit facility originally dated May 10, 2021, consolidating its bank financing under the new 2026 credit agreements.
Boston Scientific Corp director Christophe Pierre Weber filed an initial statement of beneficial ownership on Form 3. The filing lists him as a director of the company and does not report any purchase, sale, acquisition, or disposition transactions in the company’s securities.
Boston Scientific Corporation director Cathy R. Smith filed an initial ownership report on Form 3. The filing shows indirect ownership of 141 shares of common stock as of February 18, 2026, held "By Trust." This is a disclosure of existing holdings, not a reported trade.
Boston Scientific Corporation expanded its Board of Directors and significantly increased its share repurchase capacity. The board grew from ten to twelve members with the appointment of Catherine R. Smith, CFO of Starbucks, and Christophe P. Weber, president and CEO of Takeda Pharmaceutical, effective February 18, 2026.
Smith joins the Audit and Nominating and Governance Committees, while Weber joins the Executive Compensation and Human Resources Committee and the Risk, Science and Technology Committee as of February 23, 2026. Each will receive prorated non-employee director compensation, including a cash retainer of approximately $24,663 and an equity award valued at approximately $42,420, vesting at the end of their terms.
The board also approved an increase to the company’s existing common stock repurchase authorization by an additional $4.0 billion, bringing the total authorization to $5.0 billion, all of which remains available under the stock repurchase program.
Boston Scientific EVP Padraig Andrew O'Connor reported multiple equity award transactions. On February 13, 14, and 16, 2026, restricted stock units covering 500, 1,190, and 905 units were exercised or converted into an equal number of Boston Scientific common shares at a stated price of $0.00 per share.
Related Form 4 entries show dispositions of 199, 449, and 339 common shares at $74.73 per share, characterized as payments of tax liability by delivering shares rather than open-market sales. Footnotes explain that each restricted stock unit represents a commitment to issue one share, generally in four equal annual installments beginning on specified February anniversaries of the grant dates.
Boston Scientific SVP Emily Woodworth reported several equity transactions involving restricted stock units and common stock. On February 13–16, 2026, she exercised restricted stock units that convert into an equal number of Boston Scientific common shares, with individual transactions including 1,413, 661, and 637 units. Corresponding common stock entries show the same share amounts acquired at a stated price of $0.0000 per share, reflecting non-cash derivative exercises. Additional common stock entries coded “F” cover 690, 296, and 283 shares delivered at $74.73 per share to satisfy tax liabilities rather than open-market sales. Footnotes state that each restricted stock unit represents a commitment to issue one share of common stock, generally in four equal annual installments beginning on specific grant anniversaries.
Boston Scientific EVP and CFO Jonathan Monson reported a series of equity award transactions. On February 13, 14 and 16, 2026, restricted stock units were converted into common stock in blocks of 1,766, 1,058 and 990 shares at $0.0000 per share, reflecting vesting of prior grants. On each date, portions of the resulting common shares (788, 470 and 440 shares) were disposed of at $74.73 per share to satisfy tax obligations through share withholding. Following these transactions, Monson directly owned 37,986 shares of Boston Scientific common stock.
Boston Scientific senior vice president and chief HR officer Miriam O'Sullivan reported multiple equity award transactions in mid‑February. She exercised restricted stock units into 588, 1,124, and 990 shares of common stock on February 13, 14, and 16, 2026 at a price of $0.00 per share.
To cover tax obligations, she disposed of 200, 329, and 291 common shares on the same dates through tax‑withholding transactions at $74.73 per share. After these moves, she directly held 17,302 Boston Scientific shares and indirectly held 1,731 shares through her spouse.
Boston Scientific Corp Chairman, President & CEO Michael F. Mahoney reported multiple equity award and vesting transactions. On February 13, 2026, he acquired 132,190 shares of common stock as a grant and another 8,832 shares through the conversion of restricted stock units, while 132,099 shares of common stock were withheld at $74.73 per share to cover tax obligations.
On February 14, 2026, 16,524 restricted stock units converted into 16,524 common shares, with 7,990 shares withheld for taxes at $74.73 per share. On February 16, 2026, 16,265 restricted stock units converted into common stock and 7,865 shares were similarly withheld for taxes at $74.73 per share.
The filing notes performance share units granted in February 2023 under organic net sales and total shareholder return programs, for which performance and service conditions were satisfied as of February 13, 2026. An additional 213,679 common shares are reported as held indirectly by trust.
Boston Scientific executive Joseph Michael Fitzgerald, EVP & Group President, Cardiology, reported multiple stock-based compensation transactions. He acquired Boston Scientific common stock through exercises of restricted stock units and performance share units, as well as grants totaling 34,898 shares of common stock on February 13, 2026.
On February 13, 14, and 16, 2026, he also had shares of common stock withheld to satisfy tax liabilities, disposing of 33,104, 1,990, and 1,806 shares at $74.73 per share, respectively, as tax-withholding dispositions rather than open-market sales. After these transactions, he directly held 213,907 shares of common stock, and 5,234 additional shares were reported as held indirectly by his child, for which he disclaims beneficial ownership.